NASDAQ:ALT - Altimmune, Inc.
$2.95
 $-0.04
-1.34%
2:15PM EDT
2019-02-15
Altimmune, Inc., formerly Pharmathene, Inc., is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies, RespirVec and Densigen. Its candidates include NasoVAX, HepTcell, NasoShield and Oncosyn. NasoVAX is an intranasally administered recombinant influenza vaccine. The Company has completed Phase I clinical trials of NasoVAX. HepTcell is being tested as an immunotherapy for patients chronically infected with the hepatitis B virus. NasoShield is an intranasal, single-dose anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. Oncosyn is being developed as a cancer immunotherapeutic product candidate. Oncosyn targets multiple tumor antigens simultaneous to prevent tumor escape. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ALT     avg for
industry  
  avg for
sector  
42 stocks weight:  -1000. 00   0. 00   0. 00  
42 stocks rank:  4. 04 K 1. 86 K 1. 09 K
# analyst opinions:  1. 00   14. 92   14. 43  

quick ratio:  1. 38   5. 37   1. 81  
current ratio:  1. 43   5. 69   2. 19  

ex-dividend date:     2017-01-19
target price low:  3. 18   88. 97   117. 82  
target price avg:  3. 18   115. 19   141. 96  
target price high:  3. 18   143. 40   163. 16  
1-yr high:  54. 54   124. 30   142. 77  
last close:  2. 99   101. 85   127. 84  
50-day avg:  2. 81   98. 27   122. 46  
200-day avg:  8. 73   99. 72   122. 70  
1-yr low:  1. 72   78. 19   100. 16  
volume:  353. 12 K 2. 38 M 4. 64 M
50-day avg volume:  489. 71 K 3. 31 M 4. 94 M
200-day avg volume:  764. 83 K 3. 23 M 4. 28 M

1-day return:  -1. 97 % 0. 22 % 0. 48 %
this week return:  -4. 78 % 1. 77 % 2. 01 %
12-wk return:  -6. 85 % 6. 56 % 3. 33 %
52-wk return:  -93. 02 % -2. 23 % 14. 35 %

enterprise value (EV):  -533. 50 K 55. 17 B 104. 51 B
market cap:  20. 59 M 49. 01 B 96. 46 B
EBITDA:  -16. 50 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  0. 03   -91. 79   2. 29  
enterprise/revenue (EV/R):  -0. 05   29. 84   23. 39  
total revenue:  10. 55 M 11. 28 B 40. 22 B
total debt:  2. 01 M 13. 73 B 16. 57 B
debt/equity:  5. 07   258. 01   110. 73  
net income (common):  -28. 83 M 2. 37 B 3. 58 B

shares outstanding:  6. 89 M 607. 99 M 1. 22 B
shares:  1. 61 M 605. 53 M 1. 15 B
shares short:  566. 41 K 11. 62 M 12. 55 M
shares short prior month:  564. 69 K 11. 95 M 13. 44 M
short ratio:  1. 72   4. 82   3. 10  
short % of float:  55. 89 % 6. 19 % 2. 82 %
total cash/share:  4. 62   12. 02   11. 46  
total cash:  7. 96 M 7. 41 B 7. 37 B
free cash flow:  -2. 49 M 95. 99 M 2. 04 B
operating cash flow:  -9. 04 M 164. 74 M 3. 04 B

book value:  23. 00   14. 43   28. 26  
price/book:  0. 13   -1. 57   -2. 97  
gross profits:  -7. 67 M 8. 28 B 18. 09 B
operating margins:  -158. 56 % -458. 01 % -642. 83 %
EBITDA margins:  -156. 39 % 13. 81 % 22. 47 %
profit margins:  -222. 67 % 6. 57 % 9. 92 %
gross margins:  -88. 17 % 49. 33 % 54. 53 %

1-yr max volatility:  285. 48 % --- ---
1-yr mean volatility:  0. 15 % 0. 01 % 0. 06 %

1-yr EPS:  -32. 96   3. 03   4. 09  
forward EPS:  -2. 06   4. 33   6. 99  
P/E:  -0. 09   6. 11   26. 91  
forward P/E:  -1. 45   8. 38   10. 48  
PE/G:  0. 00   0. 37   5. 61  
growth:  -42. 60 % 683. 72 % 104. 79 %
earnings high:  -0. 00   1. 27   1. 66  
earnings avg:  -0. 00   1. 01   1. 53  
earnings low:  -0. 00   0. 76   1. 40  
revenue high:  3. 52 M 2. 86 B 11. 19 B
revenue avg:  3. 52 M 2. 78 B 10. 84 B
revenue low:  3. 52 M 2. 67 B 10. 64 B
return on assets:  -16. 44 % -3. 27 % 3. 81 %
return on equity:  -48. 57 % 107. 48 % 27. 82 %
revenue growth:  -42. 60 % 648. 36 % 97. 70 %
revenue/share:  12. 06   14. 68   59. 83  

beta (1yr vs S&P500):  1. 94   1. 21   0. 93  
sharpe (1yr):  0. 12   0. 06   0. 98  

held % insiders:  14. 29 % 6. 46 % 3. 21 %
held % institutions:  1. 67 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : ALT
.        + 0 =             0 :: INITIAL WEIGHT
.  + 233.764 =       233.764 :: inverse volume-to-price addition
.  + 336.784 =       570.548 :: spline projection addition
.  - 289.883 =       280.665 :: poor performance penalty
.    x 0.426 =       119.553 :: one-year gains+dividend factor
.    x 3.728 =       445.691 :: 13 weeks' performance factor
.    x 1.492 =       665.189 :: industry recommendation factor
.    x 0.998 =       664.095 :: return on assets factor
.    x 0.995 =        660.87 :: return on equity factor
.    x 0.996 =       658.055 :: revenue growth factor
.    x 2.252 =      1481.849 :: current ratio factor
.    x 1.621 =      2402.542 :: quick ratio factor
.    x 1.258 =      3021.281 :: short ratio factor
.    x 2.001 =      6046.491 :: price-to-book factor
.     x 1.01 =      6105.609 :: debt-to-equity factor
.    x 5.697 =     34784.096 :: EBITDA multiple factor
.    x 1.081 =     37602.421 :: 5-day avg > 50-day avg
.    x 2.177 =     81858.566 :: P/E weight
.    x 2.209 =    180822.225 :: PE/G factor
.    x 1.521 =    275085.481 :: beta factor
.    x 0.119 =     32826.814 :: sharpe factor
.    x 1.254 =     41164.978 :: target low factor
.    x 1.085 =      44652.05 :: target mean factor
.    x 1.025 =     45786.788 :: target high factor
.    x 1.066 =     48790.987 :: industry 12-weeks return
.    x 0.906 =     44213.052 :: "drift" penalty 2 days ago
.     x 0.99 =     43757.654 :: overall "drift" factor
.    x 0.406 =     17784.852 :: largest single-day jump factor
.     x 0.07 =      1253.337 :: low price factor
.      x 1.0 =      1253.421 :: factor hist industry gain for week 06
.   cubeRoot =        10.782 :: reduced for readability
.                   -999.999 :: FINAL WEIGHT for NASDAQ:ALT


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org